Home › Compare › CWEGF vs ABBV
CWEGF yields 36.30% · ABBV yields 3.06%● Live data
📍 CWEGF pulled ahead of the other in Year 1
Combined, CWEGF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CWEGF + ABBV for your $10,000?
Crew Energy Inc. engages in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids (NGL) in Canada. It primarily holds interests in Septimus, West Septimus, Groundbirch/Monias, Tower, and Attachie, areas located in the southwest, south, and west of Fort St. John in British Columbia. As of December 31, 2021, the West Septimus area had proved plus probable reserves of 51,559.2 thousand barrels (Mbbl) of NGL and 893,110 million cubic feet (Mmcf) of conventional natural gas; the Septimus area comprised of proved plus probable reserves of 4,257.6 Mbbl of light and medium crude oil, and 11,568.9 Mbbl of NGL along with 368,407 Mmcf of conventional natural gas; the Groundbirch/Monias area had total proved plus probable reserves of 9,500.5 Mbbl of NGL and 461,168 Mmcf of conventional natural gas; the Tower area comprised proved plus probable reserves of 1,599.2 Mbbl of light and medium crude oil, 619.2 Mbbl of NGL, and 23,364 Mmcf of conventional natural gas; and the Attachie area comprised proved plus probable reserves of 6,753.4 Mbbl of NGL and 164,970 Mmcf of conventional natural gas The company was incorporated in 2003 and is headquartered in Calgary, Canada.
Full CWEGF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.